200,000+ products from a single source!

sales@angenechem.com

Home > Iodo > 167817-55-2

167817-55-2

167817-55-2 | L-Phenylalanine, 2-iodo-

CAS No: 167817-55-2 Catalog No: AG001XLY MDL No:MFCD01860665

Product Description

Catalog Number:
AG001XLY
Chemical Name:
L-Phenylalanine, 2-iodo-
CAS Number:
167817-55-2
Molecular Formula:
C9H10INO2
Molecular Weight:
291.0857
MDL Number:
MFCD01860665
IUPAC Name:
(2S)-2-amino-3-(2-iodophenyl)propanoic acid
InChI:
InChI=1S/C9H10INO2/c10-7-4-2-1-3-6(7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)/t8-/m0/s1
InChI Key:
BKXVGLPBXYBDDM-QMMMGPOBSA-N
SMILES:
OC(=O)[C@H](Cc1ccccc1I)N

Properties

Complexity:
187  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
0
Exact Mass:
290.976g/mol
Formal Charge:
0
Heavy Atom Count:
13  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
291.088g/mol
Monoisotopic Mass:
290.976g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
63.3A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-0.9  

Literature

Title Journal
Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma. European journal of nuclear medicine and molecular imaging 20101201
99mTc-tetrofosmin SPECT for the evaluation of cerebral lesions. European journal of nuclear medicine and molecular imaging 20101201
Preliminary in vivo evaluation of [131I]-2-iodo-D-phenylalanine as a potential radionuclide therapeutic agent in R1M-fluc rhabdomyosarcoma tumor-bearing NuNu mice using bioluminescent imaging. Cancer biotherapy & radiopharmaceuticals 20100401
PET imaging with p-[I-124]iodo-l-phenylalanine as a new tool for diagnosis and postoperative control in patients with glioma. Clinical nuclear medicine 20080601
The use of [123I]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: in vitro R1M rabdomyosarcoma cell and in vivo mouse experiments. Cancer biotherapy & radiopharmaceuticals 20080401
Intra-individual comparison of the human biodistribution and dosimetry of the D and L isomers of 2-[123I]iodo-phenylalanine. Nuclear medicine communications 20071001
Optimization by experimental design of precursor synthesis and radiolabeling of 2-iodo-L-phenylalanine, a novel amino acid for tumor imaging. Cancer biotherapy & radiopharmaceuticals 20060601
Comparative biodistribution study of the new tumor tracer [123I]-2-iodo-L-phenylalanine with [123I]-2-iodo-L-tyrosine. Nuclear medicine and biology 20060101
Influence of sedation and data acquisition method on tracer uptake in animal models: [123I]-2-iodo-L-phenylalanine in pentobarbital-sedated tumor-bearing athymic mice. Nuclear medicine and biology 20060101
In vivo evaluation and dosimetry of 123I-2-iodo-D-phenylalanine, a new potential tumor-specific tracer for SPECT, in an R1M rhabdomyosarcoma athymic mouse model. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20051201
In vivo characterization of 123/125I-2-iodo-L-phenylalanine in an R1M rhabdomyosarcoma athymic mouse model as a potential tumor tracer for SPECT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20050301
Synthesis, radiosynthesis, and in vitro characterization of [125I]-2- iodo-L-phenylalanine in a R1M rhabdomyosarcoma cell model as a new potential tumor tracer for SPECT. Nuclear medicine and biology 20040801

© 2019 Angene International Limited. All rights Reserved.